Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice

Diabetologia

Volumn 58, Issue 4, 2015, Pages 845-853

  Menini, Stefano ^a   Iacobini, Carla ^a   Ricci, Carlo ^a   Fantauzzi, Claudia Blasetti ^a   Pugliese, Giuseppe ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Advanced glycation end products; AGE; Atherosclerosis; Carnosine; Reactive carbonyl species; Renal disease

Indexed keywords

3 NITROTYROSINE; 6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; CASPASE 3; CATALASE; CHOLESTEROL; COLLAGEN; COLLAGEN TYPE 4; COLLAGEN TYPE 4 A1; DEXTRO CARNOSINE OCTYLESTER; ESTER DERIVATIVE; FIBRONECTIN; GLUCOSE; GLUTATHIONE PEROXIDASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ISOPROSTANE DERIVATIVE; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTECTIVE AGENT; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CARNOSINE; CARNOSINE OCTYL ESTER;

ADULT; ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE EXPRESSION; GLOMERULOPATHY; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY MASS; MORPHOMETRICS; MOUSE; NONHUMAN; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; SMOOTH MUSCLE FIBER; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; AORTIC DISEASES; ATHEROSCLEROTIC PLAQUE; BLOOD; DEFICIENCY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE COURSE; DRUG EFFECTS; GENETICS; KIDNEY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TIME;

ANIMALS; AORTA; AORTIC DISEASES; APOLIPOPROTEINS E; ATHEROSCLEROSIS; BIOMARKERS; CARNOSINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; KIDNEY; MICE; MICE, KNOCKOUT; PLAQUE, ATHEROSCLEROTIC; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84925463624     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-014-3467-6     Document Type: Article

References (36)

1. The Diabetes Control and Complications Trial (DCCT) Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
2. UK Prospective Diabetes Study Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
3. Shichiri M, Kishikawa H, Ohkubo Y, Wake N (2000) Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23(suppl 2):B21–B29
4. The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560–2572
5. The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559
6. Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139
7. Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 22:2643–2653
8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589
9. del Prato S (2009) Megatrials in type 2 diabetes. From excitement to frustration? Diabetologia 52:1219–1226
10. Haneda M, Koya D, Isono M, Kikkawa R (2003) Overview of glucose signaling in mesangial cells in diabetic nephropathy. J Am Soc Nephrol 14:1374–1382
11. Ahmed N (2005) Advanced glycation endproducts—role in pathology of diabetic complications. Diabetes Res Clin Pract 67:3–21
12. Negre-Salvayre A, Coatrieux C, Ingueneau C, Salvayre R (2008) Advanced lipid peroxidation end products in oxidative damage to proteins. Potential role in diseases and therapeutic prospects for the inhibitors. Br J Pharmacol 153:6–20
13. Ellis EM (2007) Reactive carbonyls and oxidative stress: potential for therapeutic intervention. Pharmacol Ther 115:13–24
14. Goh SY, Cooper ME (2008) The role of advance glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 93:1143–1152
15. Aldini G, Maffei Facino R, Beretta G, Carini M (2005) Carnosine and related dipeptides as quenchers of reactive carbonyl species: from structural studies to therapeutic perspectives. Biofactors 24:77–87
16. Vistoli G, Orioli M, Pedretti A et al (2009) Design, synthesis, and evaluation of carnosine derivatives as selective and efficient sequestering agents of cytotoxic reactive carbonyl species. ChemMedChem 4:967–975
17. Menini S, Iacobini C, Ricci C et al (2012) D-Carnosine octylester attenuates atherosclerosis and renal disease in ApoE null mice fed a Western diet through reduction of carbonyl stress and inflammation. Br J Pharmacol 166:1344–1356
18. Branen L, Pettersson L, Lindholm M, Zaina S (2001) A procedure for obtaining whole mount mouse aortas that allows atherosclerotic lesions to be quantified. Histochem J 33:227–229
19. Iacobini C, Menini S, Ricci C et al (2009) Accelerated lipid-induced atherogenesis in galectin-3 deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol 29:831–836
20. Iacobini C, Menini S, Oddi G et al (2004) Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury. Evidence for a protective role of galectin-3 as an AGE-receptor. FASEB J 18:1773–1775
21. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK (2000) Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523–531
22. Bondeva T, Heinzig J, Ruhe C, Wolf G (2013) Advanced glycated end-products affect HIF-transcriptional activity in renal cells. Mol Endocrinol 27:1918–1933
23. Bharadwaj LA, Davies GF, Xavier IJ, Ovsenek N (2002) l-carnosine and verapamil inhibit hypoxia-induced expression of hypoxia inducible factor (HIF-1 alpha) in H9c2 cardiomyoblasts. Pharmacol Res 45:175–181
24. Tan SM, Sharma A, Stefanovic N et al (2014) A derivative of Bardoxolone methyl, dh404, in an inverse dose-dependent manner, lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. Diabetes 63:3091–3103
25. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272:17810–17814
26. Menini S, Iacobini C, Ricci C et al (2007) Ablation of the gene encoding p66Shc protects mice against AGE-induced glomerulopathy by preventing oxidant-dependent tissue injury and further AGE accumulation. Diabetologia 50:1997–2007
27. Decker EA, Livisay SA, Zhou S (2000) A re-evaluation of the antioxidant activity of purified carnosine. Biochemistry (Mosc) 65:766–770
28. Velez S, Nair NG, Reddy VP (2008) Transition metal ion binding studies of carnosine and histidine: biologically relevant antioxidants. Colloids Surf Biointerfaces 66:291–294
29. Fujita H, Fujishima H, Chida S et al (2009) Reduction of renal superoxide dismutase in progressive diabetic nephropathy. J Am Soc Nephrol 20:1303–1313
30. Gordon S, Lawson L, Rabinowitz S, Crocker PR, Morris L, Perry VH (1992) Antigen markers of macrophage differentiation in murine tissues. Curr Top Microbiol Immunol 181:1–37
31. Basta G, Schmidt AM, de Caterina R (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 63:582–592
32. Aldini G, Orioli M, Rossoni G et al (2011) The carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in Zucker obese rats. J Cell Mol Med 15:1339–1354
33. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M (1998) Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 339:69–75
34. Nissen SE, Nicholls SJ, Sipahi I et al (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295:1556–1565
35. Chalmers J, Cooper ME (2008) UKPDS and the legacy effect. N Engl J Med 359:1618–1620
36. Hanssen NM, Wouters K, Huijberts MS et al (2014) Higher levels of advanced glycation endproducts in human carotid atherosclerotic plaques are associated with a rupture-prone phenotype. Eur Heart J 35:1137–1146